Measuring fractional exhaled nitric oxide (FeNO) provides a relatively fast and easy quantitative measure of airway inflammation. Clinicians may use this test to evaluate and compare allergic airway inflammation in patients with underlying asthma, chronic cough evaluations and other respiratory issues. However, sponsors often struggle to capture quality data as the protocol to collect and measure FeNO is complex and requires investigative site personnel to closely follow a sequence of manoeuvres prior to conducting a standard spirometry test.
Join Dr. Kathy Rickard, Vice President, Medical Development at Circassia Pharmaceuticals and Christian Bechinie von Lazan, Product Manager at ERT for an in-depth presentation on the value of FeNO testing and a discussion of the main factors impacting measurement and data quality. Measurement devices, acceptability and repeatability, reference values and reporting of results, and quality control best practices will be reviewed. The presentation will also explore how centralized FeNO solutions and device integration will increase protocol compliance, improve patient performance and reduce investigative site burden in respiratory clinical trials for Asthma, COPD, ACOS, occupation medicine, and other clinical research.